← Back to Search

Diagnostic Imaging with 64Cu-PSMA-I&T for Prostate Cancer

Phase 2
Waitlist Available
Research Sponsored by Curium US LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights

Study Summary

This trial evaluates a new imaging technique to detect recurrent prostate cancer after treatment.

Eligible Conditions
  • Prostate Cancer Metastasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Adverse Events
Patient-Level Correct Detection Rate (CDR)
Region-Level Correct Localization Rate (CLR)
Secondary outcome measures
Score of Image Quality

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic Imaging with 64Cu-PSMA-I&TExperimental Treatment1 Intervention
64Cu-PSMA I&T
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
64Cu-PSMA I&T
2022
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

Curium US LLCLead Sponsor
5 Previous Clinical Trials
982 Total Patients Enrolled
2 Trials studying Prostate Cancer
523 Patients Enrolled for Prostate Cancer
~12 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top